Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 10, 2006

View Archived Issues

Takeda presents highlights of previous nine months

Ferritin synthesis increased by small molecule binding to mRNA

Protection for gentamicin-evoked nephrotoxicity / News in Context

Pivotal phase II/III MS trial of MBP-8298 recommended to continue

Phase I trial investigates APD-668 for type 2 diabetes

ARYx completes Series E financing

Phase I SBIR grant supports preclinical work for ALS-886 for stroke

Oscient acquires expanded rights to ramoplanin

G2 Therapies and Novo Nordisk to collaborate on antiinflammatory therapies

Xyotax receives fast track designation for PS2 women with NSCLC

ReGen Therapeutics to acquire Sciencom

Open-label phase III extension study planned for Alzhemed in North America

FDA approves IND for first phase III bladder cancer trial for Bioniche's MCC

Selective apoptotic agent isolated from an actinomycete

MF-101 studied in phase II trial for treatment of menopausal symptoms

Generic name bremelanotide approved for PT-141

Avrina shows efficacy in eczema

Alvimopan reduces time to recover GI function following bowel resection surgery

NRP-290 bioavailability studied in phase I/II trial

Factor Xa inhibitor shows promise as an antimetastatic agent

COX-2 inhibitors reduce the risk of breast cancer

Recent patents disclose novel antiinfective agents

Novel agents for endocrine-related disorders reported in recent patent literature

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...